DNA repair by ERCC1 in non-small-cell lung cancer [2]

New England Journal of Medicine

Volumn 355, Issue 24, 2006, Pages 2590-2591

  Cecere, Fabiana ^a   Bria, Emilio ^a   Rosell, Rafael ^b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; VINCA ALKALOID; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; DNA REPAIR; LUNG TUMOR; METABOLISM; MORTALITY; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING;

EID: 33845494722     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc062783     Document Type: Letter

References (1)

1. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.